Neural Analytics Inc announces the receipt of FDA 510(k) clearance for its NeuralBot System, a robotic assistance technology that aids in the diagnosis of neurological disorders.
The NeuralBot System is designed to automatically adjust the orientation and position of its ultrasound products under the guidance of a healthcare professional.
When used with its previously FDA-cleared Lucid M1 Transcranial Doppler Ultrasound System, it can help clinicians noninvasively measure and display a patient’s brain blood flow characteristics and provide information to help diagnose neurological disorders.
Neural Analytics will immediately commercialize the NeuralBot System with its currently available Lucid M1 TCD System in the US as the Lucid Robotic System. The Lucid Robotic System, when used for a transcranial doppler ultrasound procedure for patients suspected of neurological disorder, is reimbursable by Medicare/Medicaid and most private payors, according to a media release from the company.
“Progress in treating neurological disorders has lagged due to a lack of available low-cost and objective patient diagnostic information. This has resulted in misdiagnosis, treatment delays and additional healthcare expenditures for patients suffering neurological disease,” says Robert Hamilton, PhD, co-founder and chief scientific officer at Neural Analytics, in a media release.
“Our new technology can assist a healthcare professional—when an expert technician is not available—with the collection of blood flow data to assist clinicians in efficiently triaging patients for appropriate treatment.”
[Source(s): Neural Analytics Inc, Business Wire]
